company coverage
Neuren Pharmaceuticals Limited research (ASX:NEU)
Coverage of Neuren Pharmaceuticals Limited collects dated research on business quality, return drivers, balance-sheet resilience, valuation scenarios, and what would change the thesis for ASX:NEU.
2 editions linked in this hub.
Coverage
- 5 Aug 2026Neuren's DAYBUE pop prices a royalty upgrade before Japan answersNeuren Pharmaceuticals (ASX:NEU) jumped after DAYBUE sales upgraded royalties; we test whether the rally outruns pipeline proof.
- 29 June 2026Neuren's European Daybue jump puts one-drug royalties ahead of the pipelineNeuren (ASX:NEU) jumped after Daybue won an EU approval positive opinion; the question is how much royalty duration the tape just capitalised.